Towards a precision medicine in venous thromboembolism associated to lung cancer

Oncological patients have a higher risk for venous thromboembolism (VTE) (1,2), and also have an elevated risk of VTE recurrence and bleeding (3-5). Actually, guidelines in oncological patients with VTE recommend anticoagulant treatment, although these recommendations are the same, irrespectively of cancer and VTE location (6-9).